Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. by McMillan, CV et al.
 Clinical Endocrinology (2003) 
 
58
 
, 436–445
 
436
 
© 2003 Blackwell Publishing Ltd
 
Blackwell Science, LtdEvaluation of two health status measures in adults with 
growth hormone deficiency
 
C. V. McMillan*, C. Bradley*, J. Gibney†, 
D. L. Russell-Jones‡ and P. H. Sönksen†
 
*
 
Royal Holloway, University of London, Egham, Surrey, 
 
†
 
St Thomas’ Hospital, London and 
 
‡
 
Royal Surrey County 
Hospital, Guildford, UK 
 
(Received 6 June 2002; returned for revision 15 July 2002; finally 
revised 4 October 2002; accepted 8 November 2002)
 
Summary
 
OBJECTIVE
 
 
 
To evaluate the psychometric properties
of two health status measures for adults with growth
hormone deficiency (GHD): Nottingham Health Profile
(NHP) and Short-Form Health Survey (SF-36).
 
DESIGN
 
 
 
(1) A cross-sectional survey of adults with
treated or untreated GHD to assess reliability and validity
of the questionnaires. (2) A randomized, placebo-
controlled study of 3 months’ GH withdrawal from
GH-treated adults to assess the sensitivity of the
questionnaires to change.
 
PATIENTS
 
 
 
(1) A cross-sectional survey of 157 patients
with severe GHD (peak GH < 10 mU/l on provocative
testing), mean age 48·9 years (range 23–70 years), who
had either received GH replacement therapy for at least
6 months immediately prior to the study or had not
received GH treatment in the previous 6 months. (2) GH
treatment was withdrawn from 12 of 21 GH-treated
adults, all with severe GHD (peak GH < 7·7 mU/l on
provocative testing), mean age 44·9 years (range
25–68 years).
 
MEASUREMENTS
 
 
 
The NHP and SF-36 were used once
in the cross-sectional survey, but twice in the GH-
withdrawal study, at baseline and end-point (after
3 months).
 
RESULTS
 
 
 
(1) Cross-sectional survey. Both question-
naires had high internal consistency reliability with
subscale Cronbach’s alphas of > 0·73 (NHP) and > 0·78
(SF-36). Calculation of an NHP Total Score, occasion-
ally reported in the literature, was shown to be inad-
visable. Overall, patients with GHD were found to have
significantly worse perceived functioning than the
UK general population in SF-36 subscales of General
Health, Bodily Pain, Social Functioning, Physical
Functioning, Role-Emotional, Role-Physical, and Vitality.
Although neither questionnaire found significant
differences between GH-treated and non-GH-treated
patients, there were correlations with duration of GH
treatment (
 
P
 
 < 0·01) for GH-treated patients in SF-36
Mental Health (
 
r
 
 = 0·29, 
 
N
 
 = 87) and SF-36 Vitality (
 
r
 
 =
0·33, 
 
N
 
 = 88), indicating improvement with increasing
treatment duration. The SF-36 was also more sensitive
than the NHP to sex differences: men had significantly
better health status compared with women (
 
P
 
 < 0·05)
in all SF-36 subscales but Mental Health, but only in one
NHP subscale (Physical Mobility). (2) GH-withdrawal
study. Significant between-group differences in change
were found in SF-36 General Health [
 
t
 
(17) = 2·76,
 
P
 
 = 0·013, two-tailed] and SF-36 Mental Health [
 
t
 
(17) =
2·41, 
 
P
 
 = 0·027, two-tailed]: patients withdrawn from GH
reported reduced general health and mental health at
end-point. The NHP found no significant change.
 
CONCLUSIONS
 
 
 
The SF-36 is a better measure than
the NHP of health status of people with GH deficiency
because of its greater discriminatory power, with abil-
ity to detect lesser degrees of disability. It also has
superior sensitivity to some subgroup differences and
superior sensitivity to change compared with the NHP.
The SF-36 is highly acceptable to respondents, and
has very good internal consistency reliability. The SF-
36 is recommended to measure the health status of
adults with GH deficiency.
 
The physical symptoms of adult growth hormone deficiency
(GHD) include abnormal body composition with reduced lean
body mass and increased central adiposity; reduced muscle
strength and exercise performance (Carroll 
 
et al
 
., 1998). How-
ever, psychological symptoms may be as important as physio-
logical (Powrie 
 
et al
 
., 1995) and it has been recommended that
psychological variables should be considered when assessing
patients for treatment (Bengtsson 
 
et al
 
., 2000). Psychological
symptoms reported by adults with untreated GHD include low
energy, tiredness, sleepiness, poor concentration, poor memory,
irritability (Hunt 
 
et al
 
., 1993), anxiety, depression and mood
swings (Wallymahmed 
 
et al
 
., 1996).
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Health status has been one of the key psychological outcomes
in adult GHD research, and the Nottingham Health Profile (NHP)
(Hunt 
 
et al
 
., 1985) the most frequently used health status
questionnaire with this patient group. The NHP has six subscales
to measure Emotional Reactions, Energy, Pain, Physical Mobil-
ity, Sleep and Social Isolation. After 6 months of GH treatment
in placebo-controlled studies, improvements have been found in
Energy (McGauley 
 
et al
 
., 1990; Mardh 
 
et al
 
., 1994; Carroll 
 
et al
 
.,
1997; Wallymahmed 
 
et al
 
., 1997), Emotional Reactions (Carroll
 
et al
 
., 1997), Physical Mobility and Social Isolation (Attanasio 
 
et al
 
.,
1997; Carroll 
 
et al
 
., 1997). One study only obtained significant
improvement in Emotional Reactions and Energy when patients
with floor baseline scores (good health status) were excluded from
analysis (Burman 
 
et al
 
., 1995). Others only found improvements
in some NHP variables in the open label stages of the trial after
more than 12 months of GH treatment (Mardh 
 
et al
 
., 1994; Cuneo
 
et al
 
., 1998) or after 20–50 months (Wiren 
 
et al
 
., 1998). Some studies
found no significant effects using the NHP (Whitehead 
 
et al
 
., 1992;
Baum 
 
et al
 
., 1998). Thus energy has generally been found to improve
when patients with GHD are given GH replacement therapy, but
results for other aspects of health status have not always been
consistent. The Short-Form Health Survey (SF-36), a more recent
measure of health status (Ware & Sherbourne, 1992), has eight
subscales to measure Bodily Pain, General Health, Mental Health,
Physical Functioning, Role-Emotional, Role-Physical, Social Func-
tioning and Vitality. It has been used less frequently than the NHP
in research into adult GHD, generally in comparison studies.
Both the NHP and the SF-36 measure how people feel about
their health, but they have often been inappropriately referred to
as measures of quality of life (QoL) in the research literature,
where the terms ‘health status’ and ‘quality of life’ are frequently
misused and treated as if they were interchangeable (Smith 
 
et al
 
.,
1999; Bradley, 2001). Even if people feel that their health is poor,
they may or may not also feel that their QoL is impaired, and
vice versa. Treatments that improve health may conversely dam-
age QoL, and may lead to poor adherence to therapy. ‘When a
health-status measure is used to assess quality of life, the con-
clusions can be misleading’ (Bradley, 2001).
GH replacement therapy in adult GHD is not the norm in the
UK, as there is controversy about whether the benefits outweigh
the high financial costs and a treatment regimen requiring daily
injections. Measures of psychological outcomes are required in
addition to clinical outcomes to assess the effects of GH treat-
ment. The frequently used NHP does not appear to have been
previously validated psychometrically for use in adult GHD, and
the opportunity was taken in the two studies described in the
following, not only to validate the NHP but also to compare its
properties with those of the SF-36, which has been shown to be
more sensitive than the NHP in the general population (Brazier
 
et al
 
., 1992). The first study was a cross-sectional survey of 157
adults with severe GHD, both GH-treated and non-GH-treated,
to investigate reliability, factor structure and construct validity
of the questionnaires. Sensitivity to change was investigated in
a randomized placebo-controlled study of 3 months’ withdrawal
of GH treatment from 12 of 21 GH-treated adults, where nine
continued with GH. The Guy’s and St Thomas’ Hospital Trust
Ethics Committee gave approval for both studies.
 
The questionnaires
 
NHP
 
The NHP has 38 dichotomous negatively worded items. ‘No’
responses (indicating good functioning) score zero, ‘yes’ responses
can be weighted as described in the manual (Hunt & McKenna,
1989). Subscale scores range from 0 to 100 (lower scores indicating
better health status).
 
SF-36
 
This 36-item health survey has eight subscales with Likert scales
of two to six response options and an additional item on perceived
change in health over the previous year. SF-36 subscale scores
range from 0 to 100 (higher scores indicating better functioning).
The UK version was used in the present studies. It was found to
have high reliability with a UK general population (Brazier 
 
et al
 
.,
1992), and was able to detect low levels of ill health in people
who had scored 0 (indicating good health) on the NHP.
Both questionnaires have been used in the endocrine field;
for example, in hormone replacement therapy (Ryan & Rosner,
2001; Kenny 
 
et al
 
., 2002), diabetes (Anderson 
 
et al
 
., 1997; Benbow
 
et al
 
., 1998), thyroid disease (Burney 
 
et al
 
., 1999), and  Addison’s
disease (Lovas 
 
et al
 
., 2002).
 
Other questionnaires
 
Other questionnaires were also completed in the present studies,
including the General Well-being Index (Hunt & McKenna,
1992), which is the British version of the Psychological General
Well-being Index (Dupuy, 1984), the Well-being Questionnaire
(Bradley, 1994), and a new hormone deficiency-specific individual-
ized QoL questionnaire (HDQoL) (Bradley, 1999), the results
for which have been reported previously (McMillan & Bradley,
2000; McMillan, 2001; McMillan 
 
et al
 
., 2001).
 
The cross-sectional survey of GH-treated and 
non-GH-treated adults with GHD
 
Recruitment procedures
 
All participating patients had been diagnosed with GHD and received
GH replacement therapy for at least 6 months immediately prior
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to the study or had not received GH treatment in the previous
6 months; they were aged between 18 and 70 years; and had
received appropriate adrenal, thyroid and gonadal hormone
replacement therapy, as required by their hormonal condition, for
at least 12 months prior to the study. Patients might have adult-
onset GHD (AOGHD) or childhood-onset GHD (COGHD).
Exclusion criteria were diabetes mellitus, active malignancy or
pregnancy. The patients were to be severely GH deficient, as
determined by an insulin tolerance test (ITT) or pituitary function
test in which insulin reduced blood glucose to 
 
£
 
 2·5 mmol/ l with
peak GH concentration 
 
£
 
 10 mU/l. However, there were no ITT
results available for 21 patients because either an ITT was too
dangerous, or an ITT had never been performed or the laboratory
test results were missing from the patient notes. In 18 of these
21 cases the assumption was made that because the patients were
already receiving GH treatment, were about to be given GH treat-
ment, or had received it in the past as adults, then the severity
of the deficiency had been established, and they could be included
in this study. In three cases in the non-GH-treated group, clini-
cians were consulted about the patient’s suitability for inclusion.
Some patients were approached in a mailshot enclosing the ques-
tionnaires, others at weekly clinics.
 
Statistical analyses
 
Normality issues. 
 
Normality of distributions was investigated
through standardized 
 
z
 
 (skew) values (Tabachnik & Fidell, 1983).
Item data were not transformed to normality, thereby sacrificing
some of the accuracy of factor analyses for the convenience of
having interpretability of original units. The assumption was
made that if reliability were high, the factor analysis robust, and
the number of respondents sufficiently high, then a degree of non-
normality was acceptable. In subgroup analyses, Mann–Whitney
tests were performed on skewed variables, and 
 
t
 
-tests on normal
data.
 
Internal consistency reliability. 
 
Cronbach’s alpha coefficients
(Cronbach, 1951) were determined, with acceptable alphas rang-
ing from 0·7 (Todd & Bradley, 1994) to 0·95. Acceptable item-
total correlations were > 0·2 (Kline, 1993).
 
Factor structure. 
 
This was explored with principal components
analysis. Forced one-factor solutions were obtained for indi-
vidual subscales to confirm the validity of calculating subscale
totals. Salient loadings were taken as 
 
‡
 
 0·4, higher than the
recommended minimum 0·3 (Kline, 1994), erring on the side of
caution in an effort to reduce the risk of spurious loadings that
owed their origin to non-normality of item distributions.
 
Construct validity. 
 
This was sought in some expected subgroup
differences (GH-treated patients having generally better health
status than non-GH-treated patients, and men better than women).
Health status was expected to improve with increasing dura-
tion of treatment and correlations were undertaken (for GH-
treated patients).
 
‘Familywise’ error in multiple tests. 
 
The Holm’s sequential
Bonferroni procedure for multiple tests, cited in Green 
 
et al
 
.
(1997), was adopted. A minimum significance value of 0·006 was
required if eight similar statistical tests were performed on the
eight subscales of the SF-36 and 0·008 for the six-subscale NHP.
Analysis was conducted using SPSS for Windows (Release 7·5).
 
Results
 
The patient sample
 
Of 219 questionnaires distributed, 163 were returned (74·4%
response rate), but six patients did not meet all inclusion criteria
(e.g. were found to have diabetes mellitus), leaving 157 data sets
for analysis. Fifty-six people either declined to participate or
did not respond (23·5% of GH-treated and 29·8% of non-GH-
treated patients).
Ninety-one GH-treated and 66 non-GH-treated patients par-
ticipated. 
 
T
 
-tests showed no significant between-treatment-group
differences in body mass index (BMI) or height (Table 1); 
 
c
 
2
 
-
tests showed no differences in numbers of men but the difference
in numbers of GH-treated women (51) and non-GH-treated
women (33) was significant. The mean age of GH-treated patients
(47·1 years) was significantly lower than non-GH-treated patients
(51·3 years). There were significantly more people with COGHD
in the GH-treated group (21) than the non-GH-treated group (9).
Questionnaire completion rates were high: 98·5% (NHP) and
99·1% (SF-36) indicating high acceptability to respondents.
Non-normality (distributions skewed towards good health
status), was found in a much greater proportion of NHP items
(36/38) than SF-36 items (20/36). In fact, 31/38 dichotomous
NHP items had 
 
‡
 
 75% ‘No’ responses, indicating good health,
and 23·7% of respondents scored ‘No’ on all 38 NHP items. The
highest levels of dysfunction in the whole patient sample, found
by the NHP, were for Energy (mean 34·28 
 
–
 
 39·48, 
 
N
 
 = 153) and
Sleep (21·34 
 
– 
 
30·65, 
 
N
 
 = 153). The SF-36 found the highest
dysfunction in Vitality (mean 49·59 
 
–
 
 23·8) and General Health
(56·0 
 
–
 
 25·04). However, when compared with the results for
the UK general population (Garratt 
 
et al
 
., 1993), the patient
sample as a whole was found to have significantly worse perceived
functioning in SF-36 subscales of General Health, Bodily Pain,
Social Functioning, Physical Functioning, Roles Emotional
and Physical, and Vitality (Table 2). These results were similar
to those found by other researchers when comparing healthy
controls and patients with GHD, e.g. in the Belgian population
(Hakkaart-van Roijen 
 
et al
 
., 1998).
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Reliability analyses
 
NHP. 
 
All subscale alpha coefficients were acceptable (range
0·74–0·89) and corrected item-total correlations within subscales
were satisfactory (range 0·22–0·62). Reliability analysis of the
whole NHP scale found a high Cronbach’s alpha (0·92) but also
indicated the unacceptability of the NHP Total Score occasion-
ally reported in the literature, as corrected item-total correlations
for two items failed to reach the 0·2 criterion.
 
SF-36. 
 
All subscale alphas were high for short scales of from two
to 10 items (range 0·78–0·94) and corrected item-total correlations
within subscales were satisfactory (range 0·43–0·89).
 
Factor analysis
 
NHP. 
 
Forced one-factor analyses of the individual subscales
found satisfactory loadings 
 
‡
 
 0·4 for all except one Physical
Mobility item that loaded at 0·321. A forced one-factor analysis
of the whole scale found 10/38 items loading at < 0·4, again
indicating the invalidity of calculating an overall NHP Total
Score.
 
SF-36. 
 
Forced one-factor analyses of subscales found all loadings
satisfactory (
 
‡
 
 0·57).
With the exception of NHP Physical Mobility, analyses sup-
ported the calculation of NHP and SF-36 subscale scores for
adults with GHD.
 
Subgroup differences: GH-treatment group differences
 
NHP. 
 
There were no significant differences on Mann–Whitney
tests between the treatment groups (
 
P
 
-values in the range 0·16
to 0·99), although trends were in the expected direction of those
receiving GH treatment having better health status than non-GH-
treated patients on all subscales except Social Isolation.
 
SF-36. T
 
-tests were performed on all SF-36 subscales but the
skewed Physical and Social Functioning subscales, for which
Mann–Whitney tests were conducted. There were no significant
between-treatment-group differences: 
 
P
 
-values were in the
range 0·09 (Mental Health) to 0·83 (Role-Emotional). GH-treated
patients had slightly better functioning than non-GH-treated
patients in all subscales but Bodily Pain, Mental Health and
Physical Functioning. A further analysis, excluding the 21
patients who did not meet the initial inclusion criteria (no ITT
test result available), did not find any significant between-
treatment-group differences.
 
Correlations with duration of GH treatment in GH-treated 
patients
 
NHP. 
 
No correlations were significant once Bonferroni correc-
tions had been applied.
GH treatment 
(N = 91)
No GH treatment 
(N = 66) P
Women 51 33  0·05
Men 40 33
COGHD 21 9 < 0·05
AOGHD 70 57
Isolated GHD 5 1
Multiple hormone deficiency 86 65
Mean age (years) [range] 47·1 – 12·6 
  [23·7–70·9]
51·3 – 12·4 
  [23·8–70·9]
< 0·05
Mean duration GHD (years) (AOGHD) 13·0 – 6·8 13·2 – 7·8
BMI (kg/m2) 27·2 – 5·5 28·0 – 5·3
Height (cm) 167·5 – 10·5 168·7 – 10·6
Table 1 Characteristics of patients in the 
cross-sectional survey
Table 2 SF-36 subscale means and comparison with UK general 
population
 
Subscale N Mean UK mean* P
Bodily Pain 156 68·99 – 7·48 76·9 < 0·001
General Health 152 56·00 – 25·04 68·7 < 0·001
Mental Health 156 70·79 – 19·56 73·7
Physical Functioning 157 72·06 – 24·22 79·2 < 0·001
Role-Emotional 156 64·96 – 39·49 75·0 < 0·01
Role-Physical 155 58·92 – 40·23 76·5 < 0·001
Social Functioning 156 73·56 – 26·86 78·6 < 0·05
Vitality 157 49·59 – 23·8 61·2 < 0·001
Subscale range 0–100, with higher score indicating better health status/
functioning.
*Means for a healthy UK general population, from Garratt et al. (1993).
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SF-36. Mental Health correlated significantly with duration of
GH treatment (r = 0·29, P = 0·007, N = 87) as did Vitality (r = 0·33,
P = 0·002, N = 88), indicating, as expected, improved mental health
and vitality with increased duration of treatment.
Age of onset of GHD
Neither questionnaire found significant differences in health
status between those with AOGHD or COGHD once Bonferroni
corrections had been applied (full results not supplied).
Sex differences
Men had significantly better NHP Physical Mobility and
significantly better health status in all SF-36 subscales except for
Mental Health compared with women (Table 3). These are sim-
ilar to results for the UK general population (Brazier et al., 1992).
The randomized placebo-controlled trial of withdrawal 
of GH treatment from GH-treated adults
Study design
Patients were allocated to placebo or continued treatment with
GH in a randomized, double-blind, placebo-controlled, parallel-
groups study, in which patients self-administered either GH
(0·125–0·25 IU/kg body weight /week) or placebo for a period
of 3 months. Lilly Industries Ltd supplied the vials of GH
(Humatrope), which were indistinguishable from placebo. IGF-
I was measured by double-antibody radioimmunoassay after
acid/ethanol extraction, using a commercially available reagent
pack [Amersham, Arlington Hts, III, within-assay coefficient of
variance (CV) < 5%]. Questionnaires were given at baseline and
end-point, 3 months later. All patients were attending the
Endocrine Clinic of St Thomas’ Hospital, London.
Recruitment procedures
Inclusion and exclusion criteria were similar to those in the cross-
sectional study except that all participating patients had received
GH replacement therapy for at least 6 months immediately prior
to the study; were aged between 22 and 70 years; and were taking
adequate contraception, if women of childbearing age and
potential. All patients had endogenous GH levels of £  7·7 mU/l
at blood glucose £  2·0 mmol/ l on provocative testing. Additional
exclusion criteria were: clinically significant pulmonary, cardi-
othoracic, renal or neuromuscular disease; clinically apparent
chromosomal or genetic malformation syndromes; a history of
alcohol or drug abuse; were unlikely to comply with the protocol;
were taking oral and parenteral steroids, other than in replacement
doses, that were likely to suppress the action of GH. Prospective
participants were approached personally by clinicians.
Additional measures
Interviews were also conducted, results for which have been
reported (McMillan, 2001). The number of serious negative life
events and difficulties occurring in the 12 months prior to this
study was assessed in the interviews using a short checklist
(unpublished, available from the author, Dr Bernice Andrews, at
the Department of Psychology, Royal Holloway, UK), modified
from a screening checklist for stressful life events and chronic
difficulties (Costello & Devins, 1998).
Hypotheses
When adults with GHD are given GH treatment, improvements
in health status have been reported. There was general clinical
expectation of deterioration in physiological /metabolic factors
within the 3-month study period and that this might be accom-
panied by reduced health status (Sönksen et al., 1991). It was
therefore hypothesized that after 3 months’ withdrawal of GH
the placebo group would exhibit, relative to baseline, decrea-
sed Energy, Emotional Reactions, Physical Mobility, Sleep and
increased Social Isolation (higher scores on NHP); and decreased
General Health, Mental Health, Physical Functioning, Social
Functioning, and Vitality (reduced scores on SF-36), but GH-
treated patients would show little change.
Table 3 Means for men and women in the cross-sectional survey
 
Men Women P
NHP
Emotional Reactions 11·92 – 18·49 19·79 – 27·37
Energy 26·39 – 35·9 41·28 – 41·37
Pain 7·70 – 19·6 13·91 – 24·97
Physical Mobility 7·44 – 15·96 12·59 – 18·01 < 0·01
Sleep 17·70 – 29·06 24·65 – 31·85
Social Isolation 13·58 – 23·78 16·98 – 26·2
SF-36
Bodily Pain 78·06 – 23·99 61·23 – 28·03 < 0·001
General Health 62·28 – 22·87 50·35 – 25·70 < 0·01
Mental Health 73·81 – 18·32 68·14 – 20·33
Physical Functioning 80·43 – 19·75 64·79 – 25·47 < 0·001
Role-Emotional 73·97 – 35·24 57·03 – 41·49 < 0·05
Role-Physical 71·00 – 37·84 48·17 – 39·44 < 0·001
Social Functioning 78·60 – 25·89 69·13 – 27·07 < 0·05
Vitality 54·38 – 23·76 45·42 – 23·18 < 0·05
Minimum N 68 (NHP) 77 (NHP)
72 (SF-36) 80 (SF-36)
Subscale scores range 0–100, higher score indicating better health status 
on SF-36, but poorer health status on NHP.
Values are means – SD.
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Statistical analyses
T-tests or Mann–Whitney tests were conducted on the differences
between the treatment-group change scores over the withdrawal
period. Bonferroni corrections were not applied to reduce the
chance of Type II errors in a study with small sample size, and
as it was unlikely that a significant result that had been predicted
would be obtained by chance. The required significance level was
set at < 0·05.
Results
The patient sample
Only 66 of the 144 adults with GHD being treated with GH at
St Thomas’ Hospital fulfilled the stringent inclusion criteria and
were approached. However, 62% declined to participate, the
majority because they were satisfied with their current
treatment -  not wishing to risk withdrawal, with expected return
of undesirable symptoms of GHD. Twenty-two patients were
finally recruited into the study, but one patient withdrew from
psychological aspects of the study just prior to baseline, and
another (placebo group) withdrew suddenly and prematurely
from the study, about 2 weeks prior to end-point, owing to
adverse symptoms. There was no significant difference in the
number of men (23) and women (18) who declined to participate
in the study, or in the age of those who refused and those who
participated. The study sample was therefore representative of
the patient pool in terms of age and sex.
Table 4 shows patient characteristics. At baseline, the placebo
group had significantly higher BMI (31·3 kg/m2) compared with
the GH-treatment group (24·7 kg/m2).
Biochemical changes
Three months after baseline the serum total IGF-I of placebo-
treated patients fell from normal, age-related levels (mean 26·6 –
3·8 nmol/l) to levels indicative of severe GHD (11·6 –  1·9 nmol/ l)
(P < 0·001). Only a small, nonsignificant decrease was noted in
GH-treated patients.
One patient in the GH-treatment group reported several
adverse symptoms over the course of the withdrawal period. A
large drop (- 20·2 nmol/l or 39·3%) in his IGF-I levels were noted
over the study, well outside the mean change of - 1·74 –  10·68
for the GH-treatment group and more than the mean change of
- 15·02 –  12·38 in IGF-I levels for the placebo group. However,
his IGF-I level at end-point was in the normal range. After the
study codes had been broken, the patient was asked if there were
any reasons for this and he claimed that the injection pen may
have malfunctioned. It is also possible that he did not fully adhere
to the injection regimen, as he had a history of nonadherence.
Analyses were therefore undertaken excluding the data of this
anomalous case.
Questionnaire data
NHP. No significant between-group differences in change scores
were found in Mann–Whitney tests.
 
 
Placebo-treated
(N = 12)
GH-treated 
(N = 9) P
Men 6 4
Women 6 5
Mean age at baseline (years) [range] 45·8 [25–68] 43·8 [25–66]
Mean duration of GH treatment (months) [range] 61 [12–132] 60 [18–132]
COGHD : AOGHD ratio 2 : 10 4 : 5
BMI at baseline (kg/m2) 31·3 – 8·3 24·7 – 2·9 < 0·05
Isolated GHD 0 2
Gonadal hormone deficiency 8 6
Thyroid hormone deficiency 9 5
Corticosteroid deficiency 10 5
Antidiuretic hormone deficiency 1 1
Acromegaly 0 1
Cushing’s disease 4 1
Craniopharyngioma 1 1
Chromophobe adenoma 4 1
Macroprolactinoma 1 1
Prolactinoma 1 1
Traumatic hypopituitarism 1 0
Table 4 Characteristics of participants in the 
GH-withdrawal study
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SF-36. As expected, a significant between-group difference in
change was found in SF-36 General Health [t(17) = 2·76,
P = 0·013, two-tailed], with scores of placebo-treated patients
dropping from 63·5 –  19·6 at baseline to 57·0 –  23·2 but scores
of GH-treated patients increasing from 62·8 – 23·9 to 66·1 –
25·2, and in SF-36 Mental Health [t(17) = 2·41, P = 0·027, two-
tailed], with scores of placebo-treated patients dropping from
75·0 –  15·9 at baseline to 69·5 –  21·0 but scores of GH-treated
patients increasing from 77·5 –  20·1 to 84·5 –  7·2. Patients with-
drawn from GH reported reduced general health and mental
health at end-point. (Table 5).
Analysis of the single health transition item showed that, by
end-point, four of the 12 placebo-treated patients (33·3%), but
only one patient in the GH-treated group (the outlier whose IGF-
I levels dropped considerably), considered their health worse than
1 year before.
Discussion
The NHP has been one of the most frequently used question-
naires in research into adult GHD, yet it is known to have certain
disadvantages. It is designed for more severe illness and therefore
has highly skewed distributions in relatively healthy populations,
with reduced sensitivity to between-group differences, reduced
sensitivity to change (Bowling, 1991) and inability to detect low
levels of morbidity. Such criticisms were confirmed in the present
studies. For all individual NHP items the majority of respondents
in the cross-sectional survey answered ‘No’, that they perceived
no health problem in that area; indeed almost a quarter of
respondents reported no health problem in any of the 38 items.
The wider range of SF-36 response options means that more
information is available about different degrees of impairment,
thus the SF-36 had greater discriminatory power. Responses to
individual items of the SF-36 showed that most respondents in
the cross-sectional survey were not limited at all in moderate
activities and only felt limited in vigorous activities such as
climbing several flights of stairs. However, patients had signifi-
cantly worse health status for most SF-36 subscales than the UK
general population.
Both NHP and SF-36 have good acceptability to adults with
GHD (as indicated by high completion rates), and good internal
consistency reliability. However, reliability and factor analyses
of the whole 38-item NHP scale confirmed the inadvisability of
calculating an NHP Total Score, as occasionally reported in the
literature.
In the cross-sectional study the SF-36 showed more sensitivity
to expected sex differences than the NHP. Women had signifi-
cantly worse health status than men on all SF-36 subscales but
Mental Health, but on only one NHP subscale (Physical Mobil-
ity). In the general population, women’s health status is worse
Table 5 GH-treatment group means over the GH-withdrawal period
 
 
Placebo-treated GH-treated 
PBaseline End-point Baseline End-point
NHP
Emotional Reactions 13·86 – 24·46 14·42 – 24·91 3·78 – 7·43 0·00 – 0·0
Energy 24·95 – 35·06 26·33 – 37·89 7·90 – 15·18 7·90 – 15·18
Pain 4·12 – 10·85 5·17 – 17·14 4·77 – 9·44 5·29 – 12·77
Physical Mobility 5·42 – 15·74 7·15 – 23·73 2·75 – 7·77 5·42 – 11·60
Sleep 17·43 – 25·98 21·67 – 29·84 5·16 – 7·20 0·00 – 0·0
Social Isolation 13·13 – 24·11 13·09 – 26·10 9·68 – 14·08 0·00 – 0·0
SF-36
Bodily Pain 72·08 – 20·57 71·55 – 28·00 70·00 – 14·05 81·50 – 27·52
General Health 63·50 – 19·58 57·00 – 23·19 62·75 – 23·89 66·12 – 25·16 0·013*
Mental Health 75·00 – 15·92 69·45 – 21·04 77·50 – 20·05 84·50 – 7·23 0·027*
Physical Functioning 78·52 – 26·43 72·27 – 30·20 83·13 – 14·13 85·63 – 15·45
Role-Emotional 77·78 – 35·77 63·33 – 48·30 87·50 – 35·36 91·67 – 23·57
Role-Physical 70·83 – 39·65 72·73 – 41·01 84·38 – 18·60 90·63 – 12·94
Social Functioning 82·95 – 25·78 77·27 – 28·95 93·75 – 9·45 90·63 – 12·94
Vitality 60·00 – 22·76 51·82 – 28·40 59·38 – 15·22 60·00 – 13·63
Minimum N 11 (NHP) 11 (NHP) 8 (NHP) 6 (NHP)
11 (SF-36) 10 (SF-36) 8 (SF-36) 8 (SF-36)
*Two-tailed. Values are means –  SD.
Subscale scores range 0–100, higher score indicating better health status on SF-36, but poorer health status on NHP.
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than men’s (Hunt & McKenna, 1989; Brazier et al., 1992), and
in adult GHD women have also tended to exhibit worse health
status (NHP) than men (Burman et al., 1995). No significant
differences in health status were found between patients with
COGHD and those with AOGHD although these are different
clinical entities (Attanasio et al., 1997): CO patients are more
underdeveloped physically and AO patients have greater lipid
abnormalities. There have been few studies comparing health
status in the two groups. Although one study found no difference
in health-related QoL (Abs et al., 1999), another study found
significantly reduced physical mobility and energy in AOGHD
than COGHD (Attanasio et al., 1997).
Although the SF-36 Mental Health and Vitality subscales
showed correlations indicative of improving health status for
GH-treated patients with longer periods of GH treatment, neither
questionnaire found significant GH treatment-group differences.
It could be that neither questionnaire was sensitive to treatment-
group differences, or that there were no real differences in per-
ceived health status between the two groups. It may be that people
prescribed GH treatment present with more serious symptoms
of mental and physical ill-health but GH treatment improves their
health status to a level little different from people with GHD who
are untreated, perhaps because they are managing well without
it. The results seem to indicate that an appropriate subgroup of
patients was prescribed GH treatment -  perhaps the result of a
combination of clinical acumen and patient pressure from those
adversely affected by GHD. In the study as a whole, however,
significant findings were limited to a few selected comparisons
(e.g. sex differences and differences from the healthy general
population). Insufficient data were available to conduct further
analyses of between-group differences.
Recruitment difficulties for the GH-withdrawal study indi-
cated that the majority of patients did not want to risk withdrawal
from GH treatment, and the anticipated negative effect that it
would have on their lives. The small pool of patients suitable for
inclusion in the GH-withdrawal study, combined with a high
refusal rate, resulted in a small sample of 21 patients, and low
power of analysis. One placebo-treated patient withdrew from the
study just prior to end-point owing to adverse symptoms. The
possible nonadherence to the study protocol of one GH-treated
patient further reduced the data available for analysis. While it
might have been more logical and less problematic to investigate
the sensitivity of the questionnaires to change with GH replace-
ment, for which there would be no recruitment problems, there
was no opportunity for such a study at the time.
In the GH-withdrawal study, where health status of placebo-
treated patients was expected to worsen, the NHP found no
significant between-treatment-group differences. The SF-36,
on the other hand, had two significant findings in the expected
direction (of worsening health in the placebo group) in the General
Health and Mental Health subscales. In a study such as the
GH-withdrawal study, where power was low, the NHP was not suffi-
ciently sensitive to change. It is possible that some of the negative
findings for the benefits of GH treatment in the literature might
have been the result of the lack of sensitivity of the questionnaire
chosen to measure change, the NHP.
The relationship between hormonal abnormalities and psy-
chological consequences is complex (Fava et al., 1993). These
studies did not cover the effects of patients’ other hormone
deficiencies or endocrine disease (if any). Patients with diabetes
were excluded from the studies, and only those patients who were
being treated with appropriate adrenal, thyroid and gonadal hor-
mone replacement therapy were included. However, there is evi-
dence that some patients still exhibit psychological symptoms
(particularly depression or anxiety) even if their hormone levels
have been normalized with therapy (O’Malley et al., 2000;
Sonino & Fava, 2001; Lovas et al., 2002). Full details of other hor-
mone deficiencies were not recorded in the cross-sectional study,
although they are available for the longitudinal study. It is not
possible to say whether any psychological distress was due to
another endocrine condition, but this should be borne in mind
when interpreting results.
Conclusion
In conclusion, the present studies have shown that the SF-36 is
a better measure than the NHP of health status of people with
GH deficiency because of its greater discriminatory power, with
the ability to detect lesser degrees of disability. It also has supe-
rior sensitivity to some subgroup differences and superior sen-
sitivity to change compared with the NHP. The SF-36 is highly
acceptable to respondents, and has very good internal consist-
ency reliability. The SF-36 is recommended to measure the health
status of adults with GH deficiency.
Questionnaire availability
The NHP is available from Dr Stephen McKenna, Galen Research,
Enterprise House, Manchester Science Park, Lloyd Street North,
Manchester M15 6SE, UK.
The SF-36 is administered by the Medical Outcomes Trust, 8
Park Plaza #503, Boston, MA 02116, USA. Licence agreement
details are obtainable from www.qualitymetric.com.
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